Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Matrilin‑3 (MATN3) has been robustly associated with multiple epiphyseal dysplasia, a skeletal dysplasia characterized by delayed and irregular ossification of epiphyses, joint pain, and early‑onset osteoarthritis (PMID:12884427). Multiple independent studies across diverse populations have identified pathogenic missense mutations in MATN3 that consistently co‐segregate with the disorder, supporting its clinical relevance for diagnostic decision‑making.
The clinical presentation in affected individuals includes joint locking symptoms, abnormal cartilage architecture, and variable degrees of short stature, with radiological analyses demonstrating distinctive epiphyseal anomalies (PMID:38800255). Detailed family studies reveal autosomal dominant inheritance with several affected relatives in multiple pedigrees, underscoring the importance of segregation data in establishing causality (PMID:32264862).
Genetic evidence is substantial; case reports and multi‐patient studies have documented MATN3 mutations in over 20 unrelated probands, with several families showing clear segregation of the variant with the disease phenotype (PMID:15459972) and positive familial history (PMID:15523498). One representative pathogenic variant reported is c.382G>C (p.Ala128Pro), which has been identified in multiple affected individuals and serves as a diagnostic marker in current genetic testing algorithms.
Functional studies further corroborate the genetic findings. In vitro assays consistently demonstrate that mutant MATN3 proteins misfold and are retained within the endoplasmic reticulum, leading to impaired secretion and subsequent disruption of extracellular matrix integrity (PMID:16199550; PMID:16287128). These alterations in protein trafficking and structure explain the cartilage defects observed in patients, aligning the experimental data with clinical phenotypes.
Additional studies highlight genotype–phenotype correlations and even note that, while the majority of MATN3 mutations result in a classic MED phenotype, certain variants may lead to distinct clinical presentations, such as spondyloepimetaphyseal dysplasia, suggesting that the degree of MATN3 dysfunction can variably affect skeletal development (PMID:39293509). Despite these nuances, the overall weight of evidence supports a strong association between MATN3 mutations and multiple epiphyseal dysplasia.
In summary, the genetic and functional data converge to establish MATN3 as a critical gene in the pathogenesis of multiple epiphyseal dysplasia. The integration of case reports, multi‐patient cohorts, and in vitro functional assessments provides a cohesive narrative that is instrumental for clinical diagnostic strategies, commercial assay development, and future research publications.
Key Take‑home sentence: MATN3 mutation testing offers a powerful and reliable diagnostic tool for confirming multiple epiphyseal dysplasia, ensuring improved patient management and advancing translational research.
Gene–Disease AssociationStrongOver 20 unrelated probands with documented familial segregation (PMID:15459972; PMID:15523498) and concordant clinical findings across multiple studies support a strong association. Genetic EvidenceStrongPathogenic missense mutations, including c.382G>C (p.Ala128Pro), are reported in multiple independent case studies with autosomal dominant inheritance, providing robust genetic evidence. Functional EvidenceModerateIn vitro functional assays demonstrate that disease‐causing MATN3 mutations disrupt protein folding and secretion, consistent with an ER retention mechanism (PMID:16199550; PMID:16287128). |